Proactive Investors - Run By Investors For Investors

Cellmid granted ASX trading halt prior to capital raising news

The halt will remain in place until the start of normal trading on Tuesday, 31 July, or when the announcement is released.
ASX logo on a laptop
The life sciences company is expanding its distribution

Cellmid Limited (ASX:CDY) has been granted an ASX trading halt before releasing details of a proposed capital raising.

The securities will remain in a trading halt until the earlier of the start of normal trading on Tuesday, 31 July, or when the announcement is released to the market.

Cellmid was 46 cents at the close of trade on Thursday.

READ: Cellmid lays out major plan for product and distribution expansion

The life sciences company plans to expand distribution of products in the US and Japan as well as increase its product range in Australia.

This is expected to result in an increase in revenue in the 2019 financial year.

Cellmid’s évolis products are specifically formulated anti-ageing hair solutions, which include shampoos, conditioners, sprays and activators.

US in-store placement

For the first time évolis Professional products will be sold permanently in Neiman Marcus and Bloomingdales stores from September 2018.

The first Neiman Marcus stores designated for the full range of the évolis Professional products are Ala Moana (Hawaii), Fashion Island (California), Orlando (Florida), Northpark (Texas) and Houston (Texas).

These are flagship stores with well-trained sales associates and loyal customers.

Bloomingdales’ flagship store in New York will also carry the full évolis Professional range with other stores expected to come online in the next six months.

Launch in Japan

Cellmid aims to launch the évolis branded FGF5 inhibitor anti-ageing hair products in Japan.

The évolis Professional range was scheduled to be launched this month while the évolis Pharmacy will be launched in October.

This is the first time that the Australian manufactured products will be exported to Japan and it follows a period of extensive product testing on Japanese customers assessing both beauty and therapeutic applications.

The évolis Professional range will be progressively introduced to suitable Australian pharmacies from this month.

This will increase the number of products sold from four to 15 within the brand in these pharmacies.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

genedrive device
Here we take a closer look at Genedrive PLC (LON:GDR)
Cameron Durrant
March 05 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use